Hydrogenology
Hydrogenology editorial study record

Molecular Hydrogen for Outpatients with COVID-19 (Hydro-COVID): A Phase 3 Randomised, Triple-Blinded, Pragmatic, Placebo-Controlled, Multicentre Trial

Gaboreau Y et al. · J Clin Med. 2024;13(15):4308.

HumanH₂-rich waterPublished 2024
Study record, not medical adviceThis page reports one source and Hydrogenology’s source-text extraction. It does not establish that molecular hydrogen is effective, safe or appropriate for any person. Human, animal and laboratory evidence must not be treated as equivalent.
Source and classification

What kind of evidence is this?

Evidence stream

Human

Reported design

Phase 3 randomized triple-blind placebo-controlled multicenter trial

Research topic

Respiratory health

Administration classification

H₂-rich water

Study result signal

Not reported in this record.

Outcome type

Not reported in this record.

Reported in the source

Methods at a glance

Population or model

Outpatients with mild-to-moderate laboratory-confirmed acute COVID-19 and at least one risk factor

Sample

700 randomized; 675 included in day-30 follow-up

Duration

21 days; primary outcome at day 14 and safety follow-up at day 30

Intervention

One H₂-producing tablet in 250 mL water twice daily; 500 mL/day

Hydrogen form

H₂ dissolved in water — H₂ only, not Brown’s gas.

H₂ specification

The main article identifies Drink HRW tablets but does not report a verified delivered H₂ concentration or total H₂ dose.

H₂ flow

Not applicable — oral water, not gas inhalation.

O₂ delivered with H₂

No O₂ was co-delivered as part of the intervention.

Comparator

Matched effervescent placebo tablets in the same water volume, alongside usual care

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Clinical worsening, oxygen use, hospitalization, death, symptom resolution, persistent symptoms and adverse events

Reported result

HRW did not reduce clinical worsening: 46.1% versus 43.5%; hazard ratio 1.09, 90% CI 0.90–1.31. Adverse events were similar: 27.0% versus 26.2%.

Results-extraction completeness

Methods, primary and safety results, registration, funding and conflict statement checked in the free full text.

A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.

Interpretation limits

Cautions and applicability

Design and reporting cautions

This large trial reported a clear null primary result. Drink HRW supplied part of the study funding; authors declared no trial-related conflicts. Acute COVID-19 is distinct from Long COVID.

Applies directly to

At-risk outpatients with acute mild-to-moderate COVID-19 under the trial conditions.

Preliminary appraisal framework

Not reported in this record.

Preliminary risk-of-bias status

Not reported in this record.

Appraisal rationale

Not reported in this record.

No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.

Provenance

Sources and record status

Identifiers

PMID: 39124575 · DOI: 10.3390/jcm13154308

Publisher access

Open-access article.

Extraction basis

Free full text on PMC and publisher page; identifiers cross-checked in PubMed.

Record revision

2026-08-10